<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37558" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hydrocodone and Acetaminophen</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Habibi</surname>
            <given-names>Manuchehr</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kim</surname>
            <given-names>Peggy Y.</given-names>
          </name>
          <aff>VA Puget Sound Health Care System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manuchehr Habibi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peggy Kim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37558.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Hydrocodone is a potent analgesic commonly prescribed for moderate-to-severe pain management in postoperative settings, trauma patients, and individuals with cancer. When combined with acetaminophen, hydrocodone demonstrates increased efficacy without significantly altering the adverse effect profile, as evidenced by randomized studies. This combination is also frequently used as an antitussive agent.</p>
        <p>This activity reviews the indications, mechanism of action, pharmacokinetics, methods of administration, and potential adverse effects of hydrocodone/acetaminophen. Additionally, it outlines important precautions, contraindications, monitoring guidelines, and toxicity risks associated with this drug combination. By improving the interprofessional team&#x02019;s understanding of hydrocodone/acetaminophen, this program aims to optimize patient care and safety in pain management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of hydrocodone/acetaminophen.</p></list-item><list-item><p>Determine&#x000a0;the FDA-approved uses for initiating hydrocodone/acetaminophen therapy.</p></list-item><list-item><p>Assess&#x000a0;the adverse event profile and contraindications to using hydrocodone/acetaminophen.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to advance hydrocodone/acetaminophen therapy, improve outcomes, and minimize adverse events and misuse, especially in light of the ongoing opioid crisis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37558&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37558">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37558.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Hydrocodone is one of the most common pain medications prescribed by clinicians and one of the most abused by patients.&#x000a0;This is a relatively potent drug for moderate-to-severe pain control in postoperative patients, patients with trauma, and patients with cancer.&#x000a0;The combination of hydrocodone with acetaminophen is much more efficacious than placebo in several randomized studies without any significant changes in adverse effects.<xref ref-type="bibr" rid="article-37558.r1">[1]</xref><xref ref-type="bibr" rid="article-37558.r2">[2]</xref>&#x000a0;According to the 2023 American Geriatrics Society Beers Criteria, hydrocodone is&#x000a0;a potentially inappropriate medication&#x000a0;prescribed for&#x000a0;older adults.<xref ref-type="bibr" rid="article-37558.r3">[3]</xref></p>
      </sec>
      <sec id="article-37558.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Hydrocodone is a full opioid agonist that interacts with the &#x003bc; receptors and, to a lesser extent, with &#x003b4; receptors in the body.<xref ref-type="bibr" rid="article-37558.r4">[4]</xref> Activated &#x003bc;-opioid receptors lead to the inhibition of nociceptive pain reflexes and induce profound analgesia without affecting other sensory modalities, such as touch. Additionally, activated opioid receptors inhibit neurotransmitter release, including substance P.<xref ref-type="bibr" rid="article-37558.r4">[4]</xref></p>
        <p>Acetaminophen's mechanism of action of analgesia is not fully understood but is thought to be the result of COX inhibition and activation of descending serotonergic inhibitory pathways in the CNS. Antipyretic effects occur via inhibition of the hypothalamic heat-regulating center.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Acetaminophen is readily absorbed from the gastrointestinal tract. Hydrocodone reaches maximum serum concentrations within 1 hour with an elimination half-life of 4 to 6 hours.<xref ref-type="bibr" rid="article-37558.r5">[5]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;Plasma protein binding of acetaminophen is about 10 to 25%. The plasma half-life ranges from 1 to 3 hours; however, it may increase&#x000a0;due to liver damage following overdose.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Hydrocodone&#x000a0;is&#x000a0;metabolized by cytochrome P450-dependent oxidative metabolism and glucuronides. CYP3A4 generates&#x000a0;the metabolite norhydrocodone, and CYP2D6 generates hydromorphone.<xref ref-type="bibr" rid="article-37558.r4">[4]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Approximately 85% of the drug is eliminated in the urine within 24 hours of administration.<xref ref-type="bibr" rid="article-37558.r6">[6]</xref></p>
      </sec>
      <sec id="article-37558.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Available Dosage Forms and Strengths</bold>&#x000a0;</p>
        <p>Combination&#x000a0;hydrocodone and acetaminophen&#x000a0;is available as oral tablets and solution in the following&#x000a0;formulations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tablets
<list list-type="bullet"><list-item><p>Hydrocodone bitartrate 2.5 mg - Acetaminophen 325 mg</p></list-item><list-item><p>Hydrocodone bitartrate 5 mg - Acetaminophen 300 mg&#x000a0;</p></list-item><list-item><p>Hydrocodone bitartrate 5 mg - Acetaminophen 325 mg</p></list-item><list-item><p>Hydrocodone bitartrate 7.5 mg - Acetaminophen 300 mg</p></list-item><list-item><p>Hydrocodone bitartrate 7.5 mg - Acetaminophen 325 mg</p></list-item><list-item><p>Hydrocodone bitartrate 10 mg - Acetaminophen 300 mg</p></list-item><list-item><p>Hydrocodone bitartrate 10 mg - Acetaminophen 325 mg</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Oral Solution
<list list-type="bullet"><list-item><p>Hydrocodone bitartrate 7.5 mg - Acetaminophen 325 mg (per 15 mL)</p></list-item><list-item><p>Hydrocodone bitartrate 10 mg - Acetaminophen 300 mg (per 15 mL)</p></list-item><list-item><p>Hydrocodone bitartrate 10 mg - Acetaminophen 325 mg (per 15 mL)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Adult&#x000a0;Dosing</bold>
</p>
        <p>The CDC has provided detailed clinical practice guidelines for HCPs to refer to when prescribing opioids for pain.<xref ref-type="bibr" rid="article-37558.r7">[7]</xref>&#x000a0;The lowest dose necessary for adequate analgesia is recommended and should be titrated individually for each patient, considering the severity of pain, response, and prior analgesic experience.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tablet:</bold> For initial oral tablet therapy, the usual adult dose of hydrocodone (2.5 to 5 mg) and acetaminophen (300 to 325 mg) is&#x000a0;1 or&#x000a0;2 tablets every&#x000a0;4 to&#x000a0;6 hours as needed. The total daily dosage should not be more than&#x000a0;8 of these tablets. The maximum acetaminophen dose is 1 g per dose and 4 g&#x000a0;every 24 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Oral Solution:&#x000a0;</bold>For initial oral solution therapy, the usual adult solution dose (7.5mg - 325mg per 15 mL) is&#x000a0;1 tablespoon (15 mL) every 4 to 6 hours as needed.&#x000a0;The total daily dosage for adults should not exceed 6 tablespoons.</p>
          </list-item>
        </list>
        <p>For&#x000a0;patients&#x000a0;transitioning from other opioids to&#x000a0;hydrocodone and acetaminophen therapy,&#x000a0;clinicians should understand the dose of hydrocodone bitartrate and acetaminophen on a 24-hour basis to manage an adverse reaction due to the risk of overdose. The relative bioavailability information for conversion from extended-release hydrocodone to immediate-release hydrocodone and acetaminophen therapy is unknown. Close&#x000a0;monitoring for signs of excessive sedation and respiratory depression is recommended. The dose should be titrated on an individual basis. Continuous&#x000a0;reevaluation&#x000a0;of the dose of hydrocodone and acetaminophen&#x000a0;is needed to maintain adequate pain control, minimize adverse effects, and monitor the development of addiction, abuse, or misuse.</p>
        <p>For patients who may have a physical dependence on opioids, abrupt discontinuation of hydrocodone and acetaminophen therapy may result in severe withdrawal symptoms, uncontrolled pain, and suicidal tendencies, and hence, tapering is recommended.<xref ref-type="bibr" rid="article-37558.r8">[8]</xref></p>
        <p><bold>Specific Patients Population</bold>&#x000a0;</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The manufacturer label does not provide dose adjustment guidance for patients with hepatic impairment. However, initiating therapy with the lowest dose and continuous monitoring is recommended for these patients.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;The manufacturer label does not provide dose adjustment guidance for patients with&#x000a0;renal impairment. However,&#x000a0;26% of&#x000a0;hydrocodone and 85% of acetaminophen&#x000a0;are&#x000a0;eliminated in the urine, so the drug should be used with caution.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;This drug combination&#x000a0;is considered a pregnancy category C medicine. There is a US box warning related to pregnancy. During pregnancy, prolonged use of hydrocodone&#x000a0;and acetaminophen can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized early and treated accordingly.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Hydrocodone and acetaminophen are present in breast milk. The decision to continue or discontinue breastfeeding during therapy should be based on the risk of infant exposure versus the benefits of breastfeeding and treatment to the mother.<xref ref-type="bibr" rid="article-37558.r9">[9]</xref><xref ref-type="bibr" rid="article-37558.r10">[10]</xref></p>
        <p><bold>Pediatric patients:</bold> The dose of hydrocodone for pediatric patients is&#x000a0;titrated based on the desired analgesic effect. While considering acetaminophen dose,&#x000a0;clinicians should&#x000a0;consider the maximum daily dose of acetaminophen from all other sources, including over-the-counter, other&#x000a0;prescription, or combination products. The maximum daily dose should not exceed 2000 mg for acetaminophen to minimize hepatotoxicity maximum. Based on the information in the hydrocodone and acetaminophen oral solution label, dosing should be calculated as&#x000a0;0.27 mL/kg (equivalent to 0.135 mg/kg hydrocodone and 5.85 mg/kg acetaminophen) whenever possible.</p>
        <p><bold>Older patients:</bold>&#x000a0;To minimize the risk of falls and delirium, the initial dose should be started at the lower end of the dosing range, and patients should be monitored closely.<xref ref-type="bibr" rid="article-37558.r3">[3]</xref></p>
      </sec>
      <sec id="article-37558.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Opioid-induced constipation, dizziness, nausea, vomiting, drowsiness, and respiratory depression are common adverse reactions of hydrocodone-acetaminophen medication. There have been reports of progressive sensorineural hearing loss with chronic hydrocodone/acetaminophen use that is not responsive to high-dose steroids but responsive to cochlear implantation.<xref ref-type="bibr" rid="article-37558.r2">[2]</xref></p>
        <p>As with all opioids, tolerance to increasing doses&#x000a0;to maintain the same level of pain control and physical dependence is the most common side effect of hydrocodone. Moreover, acute and chronic opioid administration can inhibit antibody and cellular immune responses, natural killer cell activity, cytokine expression, and phagocytic activity. As a result, there are implications of opioids, pointing to an increased incidence of infections in subjects with heroin use disorder.</p>
        <p>Opioid users also&#x000a0;experience&#x000a0;endocrine changes in the body, including but not limited to sexual dysfunction, depression, and&#x000a0;reduced energy levels, resulting from hypogonadotropic hypogonadism. Also, opioid-induced hyperalgesia is a recently recognized phenomenon after patients experience increasing pain despite increasing doses of opioids.<xref ref-type="bibr" rid="article-37558.r2">[2]</xref></p>
        <p>Other adverse reactions are listed below by system.</p>
        <p><bold>Nervous:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Lethargy</p>
          </list-item>
          <list-item>
            <p>Impairment of physical and psychological performance</p>
          </list-item>
          <list-item>
            <p>Fear</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Dysphoria</p>
          </list-item>
          <list-item>
            <p>Mood changes</p>
          </list-item>
          <list-item>
            <p>Dependence</p>
          </list-item>
        </list>
        <p><bold>Genitourinary:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Ureteral spasm</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Bladder&#x000a0;sphincters spasms</p>
          </list-item>
        </list>
        <p>
<bold>Dermatological:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pruritus</p>
          </list-item>
          <list-item>
            <p>Skin rash</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>CYP3A4 and CYP2D6 inhibitors:</bold>&#x000a0;The coadministration of hydrocodone and acetaminophen&#x000a0;with CYP3A4 inhibitors&#x000a0;(eg, erythromycin, ketoconazole, ritonavir) may increase the plasma concentration of the hydrocodone, which may result in increased or prolonged opioid effects. These effects may be more pronounced when CYP3A4 and CYP2D6 inhibitors are coadministered with&#x000a0;hydrocodone and&#x000a0;acetaminophen.</p>
        <p><bold>CYP3A4 inducers:</bold>&#x000a0;The coadministration of hydrocodone and&#x000a0;acetaminophen&#x000a0;with&#x000a0;CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin) may decrease the plasma concentration of hydrocodone, which may result in reduced efficacy.</p>
        <p><bold>CNS depressants:</bold>&#x000a0;The coadministration of hydrocodone and&#x000a0;acetaminophen&#x000a0;with&#x000a0;benzodiazepines&#x000a0;or other&#x000a0;CNS depressants, due to their additive pharmacologic effect, may lead to an increase in the risk of hypotension, respiratory depression, severe sedation, coma, and death.</p>
        <p><bold>Serotonergic agents:</bold>&#x000a0;The coadministration of hydrocodone and&#x000a0;acetaminophen&#x000a0;with other drugs that affect the serotonergic neurotransmitter system (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 receptor antagonists) or with drugs that affect the serotonin neurotransmitter system (eg, mirtazapine, trazodone, tramadol cyclobenzaprine, metaxalone, monoamine oxidase inhibitors) may result in serotonin syndrome.</p>
        <p><bold>Mixed and partial agonist analgesics:</bold>&#x000a0;The coadministration of hydrocodone and&#x000a0;acetaminophen&#x000a0;with other opioid analgesics (eg, butorphanol, nalbuphine, pentazocine) may lead to reducing&#x000a0;the analgesic effect of opioids or precipitate withdrawal symptoms.</p>
        <p><bold>Muscle relaxants:</bold> The coadministration of hydrocodone and&#x000a0;acetaminophen&#x000a0;with&#x000a0;muscle relaxants may enhance the neuromuscular blocking action and induce a higher degree of respiratory depression.</p>
        <p><bold>Diuretics:</bold>&#x000a0;Hydrocodone and&#x000a0;acetaminophen may reduce the efficacy of diuretics&#x000a0;by inducing antidiuretic hormone.</p>
        <p><bold>Anticholinergic drugs:</bold>&#x000a0;The coadministration of hydrocodone and&#x000a0;acetaminophen&#x000a0;with anticholinergic drugs may increase the risk of urinary retention or severe constipation.</p>
      </sec>
      <sec id="article-37558.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hydrocodone/acetaminophen is contraindicated for patients with severe respiratory depression, acute or significant bronchial asthma, gastrointestinal obstruction, and anaphylactic reactions due to components of the formula. According to the manufacturer's label, various drugs may interact with hydrocodone/acetaminophen, and caution should be used when they are coadministered.<xref ref-type="bibr" rid="article-37558.r11">[11]</xref><xref ref-type="bibr" rid="article-37558.r12">[12]</xref></p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Hydrocodone carries the risk of opioid addiction, abuse, and misuse, which can result in overdose and death. Each patient's risk should be evaluated before prescribing the medication. All patients must be monitored for signs of the&#x000a0;behaviors or conditions listed below.</p>
        <p><bold>Life-threatening respiratory depression:</bold>&#x000a0;Serious or potentially fatal respiratory depression may occur with hydrocodone use. Patients should be regularly monitored for signs of respiratory depression, particularly during the initiation of therapy or after dose increases. Patients should be advised to swallow capsules or tablets whole. Crushing, chewing, or dissolving extended-release forms can lead to rapid release and absorption of a potentially fatal dose of hydrocodone.</p>
        <p><bold>Accidental exposure:</bold> Accidental ingestion of even a single dose of hydrocodone, particularly by children, can be fatal.</p>
        <p><bold>Neonatal opioid withdrawal syndrome:</bold>&#x000a0;For patients on opioid therapy during pregnancy, be aware that infants may need treatment for neonatal opioid withdrawal syndrome. Prolonged maternal usage of opioids during pregnancy can result in neonatal opioid withdrawal syndrome, which can be life-threatening and&#x000a0;requires careful management by neonatology specialists.</p>
        <p><bold>Co-administration with CNS depressants:</bold>&#x000a0;Administering opioids with benzodiazepines or CNS depressants, including alcohol, can lead to severe sedation, respiratory depression, coma, and even death. These combinations should be administered only when alternative treatments are insufficient, and dosages and durations should be limited to the minimum necessary.&#x000a0;Patients should be monitored for signs of respiratory depression and sedation.</p>
        <p><bold>Alcohol interaction:</bold> Co-ingestion with alcohol may increase hydrocodone plasma levels and the risk of a potentially fatal overdose by altering the drug's release from the capsule.</p>
        <p><bold>Interaction with CYP3A4 substrates:</bold>&#x000a0;Starting CYP3A4 inhibitors or stopping CYP3A4 inducers can lead to a potentially fatal overdose of hydrocodone.</p>
        <p><bold>Hepatotoxicity:</bold> Acetaminophen&#x000a0;daily doses exceeding 4 g can lead to hepatotoxicity. When assessing total daily intake,&#x000a0;clinicians must&#x000a0;consider all sources of acetaminophen, including PRN doses and over-the-counter products. Acetaminophen&#x000a0;is associated with&#x000a0;acute liver failure, which may result in death. Prescription medications containing acetaminophen should not exceed 325 mg per dosage unit.</p>
        <list list-type="bullet">
          <list-item>
            <p>Safe Dosage Guidance: Healthcare professionals may advise patients to take 1 or 2 tablets, capsules, or other dosage units of a prescription product containing 325 mg of acetaminophen up to 6 times daily (12 dosage units), ensuring the maximum daily dose of acetaminophen does not exceed 4,000 mg&#x000a0;over 24 hours.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37558.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Pain relief and adverse events should undergo frequent assessments. The dosing should start low and be titrated up as necessary to obtain adequate analgesia while having minimal side effects.</p>
        <p>Hydrocodone is a DEA Schedule II controlled substance, and it has a potential for use disorder. Patients must be monitored for addiction, abuse, and misuse signs. Additionally, patients with a prior history of drug addiction or mental illness have a higher risk of addiction.</p>
        <p>Serial liver function tests should be obtained for toxicity monitoring in patients with severe hepatic disease. Older&#x000a0;adults and patients with severe renal disease should also be monitored.</p>
        <p>Clinicians should monitor patients for the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Signs of confusion and over-sedation in older patients</p>
          </list-item>
          <list-item>
            <p>Addiction, abuse, or misuse behaviors and conditions during treatment</p>
          </list-item>
          <list-item>
            <p>Signs of respiratory depression, especially within 24 to 72 hours of treatment initiation and after dose increases</p>
          </list-item>
          <list-item>
            <p>Signs and symptoms of respiratory depression and sedation in patients susceptible to the intracranial effects of carbon dioxide retention</p>
          </list-item>
          <list-item>
            <p>Severe hypotension at the start of treatment and after dose modification</p>
          </list-item>
          <list-item>
            <p>Patients with a history of seizure disorders should be monitored for worsening seizure control</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37558.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Acetaminophen&#x000a0;may cause fatal hepatic necrosis&#x000a0;in patients taking more than 4 g per day. Furthermore,&#x000a0;large doses may cause difficulty breathing.&#x000a0;During an overdose, activated charcoal should be the first attempted intervention before N-acetylcysteine (NAC). The serum acetaminophen level should be obtained promptly for patients presenting 4 hours or longer after the ingestion.<xref ref-type="bibr" rid="article-37558.r13">[13]</xref>&#x000a0;For more information, please refer to StatPearls' companion resource, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17075">Acetaminophen Toxicity</ext-link>.&#x000a0;<bold>&#x000a0;</bold></p>
        <p>Hydrocodone intake may lead to life-threatening respiratory depression, especially if taken&#x000a0;together with benzodiazepines or other CNS depressants.&#x000a0;During an overdose,&#x000a0;the&#x000a0;priority is to protect the airways. Patients may require invasive ventilation. The opioid antagonists nalmefene and naloxone are antidotes that should be readily available for patients with respiratory depression. Opioid antagonists should&#x000a0;be avoided in the absence of clinically significant respiratory or circulatory depression. Additionally, there is a high risk of precipitating acute opioid withdrawal in a patient who is physically dependent on opioids.</p>
      </sec>
      <sec id="article-37558.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Without proper barriers and monitoring for the detrimental effects of hydrocodone and acetaminophen intoxication, the morbidity and mortality of patients using opioids can be quite significant. The drug information sheet from the manufacturer emphasizes the importance of warning patients&#x000a0;about the misuse of and addiction to hydrocodone and acetaminophen, which can lead to overdose and death. Multiple efforts point toward reducing prescription abuse and misuse.</p>
        <p>The mitigation of opioid overdose and misuse risk starts from the system-level intervention by clinicians prescribing narcotics. In addition, the Prescription Drug Monitoring Program and Medicaid managed care lock-in program require that patients receive all scripts from a single prescriber. Although over 55% dropped from the program, the proportion of stable patients (ie, patients exclusively filled&#x000a0;with&#x000a0;1 prescriber) increased from 31% to 78% at 36 months.<xref ref-type="bibr" rid="article-37558.r14">[14]</xref></p>
        <p>Pharmacists should use formulary management tools to address both opioid overprescribing and overdose. One example is a prior authorization requirement placed by the insurance companies to verify the necessary medication. Cochran et al conducted a retrospective cohort study evaluating the effects of prior authorization on the rate of abuse and overdose of patients enrolled in the Pennsylvania Medicaid program from 2010 to 2012. The study demonstrated that plans with prior authorization requirements had lower rates of use disorder and overdose.<xref ref-type="bibr" rid="article-37558.r15">[15]</xref></p>
      </sec>
      <sec id="article-37558.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37558&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37558">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37558/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37558">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37558.s11">
        <title>References</title>
        <ref id="article-37558.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Agar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nonopioid drugs in the treatment of cancer pain.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>01</day>
            <volume>32</volume>
            <issue>16</issue>
            <fpage>1677</fpage>
            <page-range>1677-90</page-range>
            <pub-id pub-id-type="pmid">24799483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benyamin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trescot</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Datta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buenaventura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Adlaka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Vallejo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Opioid complications and side effects.</article-title>
            <source>Pain Physician</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>2 Suppl</issue>
            <fpage>S105</fpage>
            <page-range>S105-20</page-range>
            <pub-id pub-id-type="pmid">18443635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarhill</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Hydromorphone: pharmacology and clinical applications in cancer patients.</article-title>
            <source>Support Care Cancer</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-96</page-range>
            <pub-id pub-id-type="pmid">11305075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>The metabolism of opioid agents and the clinical impact of their active metabolites.</article-title>
            <source>Clin J Pain</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>824</fpage>
            <page-range>824-38</page-range>
            <pub-id pub-id-type="pmid">21677572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak-Bebenista</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>JZ</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol: mechanism of action, applications and safety concern.</article-title>
            <source>Acta Pol Pharm</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-23</page-range>
            <pub-id pub-id-type="pmid">24779190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ragan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <day>04</day>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-95</page-range>
            <pub-id pub-id-type="pmid">36327391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hooten</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Opioid Management: Initiating, Monitoring, and Tapering.</article-title>
            <source>Phys Med Rehabil Clin N Am</source>
            <year>2020</year>
            <month>May</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-277</page-range>
            <pub-id pub-id-type="pmid">32279729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Hydrocodone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Acetaminophen</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monte</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Heard</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamamura</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weinshilboum</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Vasiliou</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.</article-title>
            <source>Acad Emerg Med</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>879</fpage>
            <page-range>879-85</page-range>
            <pub-id pub-id-type="pmid">25156930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Egdorf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Houston Cocktail: Driving under influence of hydrocodone, alprazolam, and carisoprodol.</article-title>
            <source>Forensic Sci Int</source>
            <year>2021</year>
            <month>Apr</month>
            <day>28</day>
            <volume>323</volume>
            <fpage>110819</fpage>
            <pub-id pub-id-type="pmid">33964487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Athersuch</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Boobis</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Coen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Possamai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective.</article-title>
            <source>Toxicol Res (Camb)</source>
            <year>2018</year>
            <month>May</month>
            <day>08</day>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-357</page-range>
            <pub-id pub-id-type="pmid">30090586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreyer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Patient Outcomes in a Medicaid Managed Care Lock-In Program.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1006</fpage>
            <page-range>1006-12</page-range>
            <pub-id pub-id-type="pmid">26521112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37558.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cochran</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gellad</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lo-Ciganic</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Donohue</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Medicaid prior authorization and opioid medication abuse and overdose.</article-title>
            <source>Am J Manag Care</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>e164</fpage>
            <page-range>e164-e171</page-range>
            <pub-id pub-id-type="pmid">28810127</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
